Anteris Technologies Global Corp(AVR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 25 at 7:30 PM ET (Korea 9/26 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.94 | Insider Own | 16.6% | Shs Outstand | 97.4M | Perf Week | -5.76% |
| Market Cap | 0.75B | Forward P/E | - | EPS next Y | 7.72% | Insider Trans | -15.63% | Shs Float | 81.3M | Perf Month | -14.08% |
| Enterprise Value | 0.50B | PEG | - | EPS next Q | -0.31 | Inst Own | 67.45% | Short Float | 7.9% | Perf Quarter | -20.64% |
| Income | -0.10B | P/S | 334.58 | EPS this Y | 51.87% | Inst Trans | -2.2% | Short Ratio | 6.46 | Perf Half Y | 42.67% |
| Sales | 0.00B | P/B | 2.98 | EPS next 5Y | 31.44% | ROA | -66.31% | Short Interest | 6.42M | Perf YTD | 54.11% |
| Book/sh | 2.58 | P/C | 2.91 | EPS past 3/5Y | -44.21% - | ROE | -75.1% | 52W High | -30.44% ($11.06) | Perf Year | 80.94% |
| Cash/sh | 2.64 | P/FCF | - | Sales past 3/5Y | -15.77% - | ROIC | -40.82% | 52W Low | 133.03% ($3.30) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.73% | Gross Margin | -2.54% | Volatility(W/M) | 4.05% 4.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 221.28 | Sales Y/Y TTM | -9.56% | Oper. Margin | -4738.36% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.2 | EPS Q/Q | 48.26% | Profit Margin | -4619.27% | RSI (14) | 34.99 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.2 | Sales Q/Q | 63.27% | SMA20 | -8.01% ($8.36) | Beta | 1.85 | Target Price | $13.8 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/10 | SMA50 | -10% ($8.54) | Rel Volume | 0.77 | Prev Close | $7.65 |
| Employees | 174 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -44.72% -32.73% | SMA200 | 7.08% ($7.18) | Avg Volume(3M) | 0.99M | Price | $7.69 |
| IPO | 2024/12/13 | Option/Short | Yes/Yes | Trades | 7240 | Volume | 762,664 | Change | 0.52% |
🫀 Anteris Technologies Global (AVR) is a medical device company specializing in structural heart disease that develops transcatheter heart valves for the treatment of aortic stenosis. Its flagship product, DurAVR, is shaped as a single-piece valve using its proprietary ADAPT tissue, aiming to deliver hemodynamic performance close to that of a native valve—differentiated from conventional sutured valves. It is a global clinical-stage company that originated in Australia and now has its key hub in Minneapolis, USA.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded less than usual That is 77% of its average volume.
AVR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +51.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $33,458. Peers typically go for $292.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 67.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #49 of 142 in the industry
Based on market cap of $749M.
VREX#46 Varex Imaging Corp $783M PER 35.4 
AHCO#47 AdaptHealth Corp $769M PER - 
QDEL#48 QuidelOrtho Corp $750M PER - AVR#49 Anteris Technologies Global Corp $749M PER - 
CTKB#50 Cytek BioSciences Inc $734M PER - 
FAQ
What kind of company is AVR?
AVR belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of AVR?
The market cap of AVR is approximately $749M, ranking 2,864 within its sector.
What is the 52-week high and low for AVR?
AVR has recorded a 52-week high of $11.06 and a low of $3.30.
